Can Ozempic cause thyroid cancer?

In rats given high doses, GLP-1 agonists caused medullary thyroid tumors — that's the source of the boxed warning. In humans, more than a decade of data including a 2024 systematic review of over 14,000 patients has found no statistically significant increase in thyroid cancer on semaglutide. The risk for patients without a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) appears very low based on current evidence.

Should I get a thyroid ultrasound before starting Ozempic?

The FDA label does not require baseline thyroid imaging, and routine ultrasound isn't standard practice for asymptomatic patients without risk factors. However, if you have a palpable neck nodule, persistent hoarseness, unexplained elevated calcitonin, or a family history of thyroid cancer of unclear type, a pre-treatment ultrasound and endocrinology consult are reasonable.

Can I take Ozempic if I have Hashimoto's thyroiditis or hypothyroidism?

Yes. Hashimoto's thyroiditis and primary hypothyroidism involve follicular cells of the thyroid, not C-cells, and are not contraindications to Ozempic. If you're on levothyroxine, expect your TSH to be rechecked after significant weight loss — levothyroxine dosing is partly weight-based, and dose reductions are common after substantial weight loss on GLP-1 therapy.

What if I have thyroid nodules?

Benign thyroid nodules are common — up to 60% of adults have some nodules on ultrasound — and are not a contraindication to Ozempic. If a nodule has suspicious features (irregular borders, microcalcifications, rapid growth), it should be evaluated with FNA biopsy regardless of whether you're on Ozempic. New or changing nodules during treatment warrant standard workup.

What symptoms should I watch for while on Ozempic that might indicate a thyroid problem?

Report a new lump or swelling in the neck, persistent hoarseness or voice changes, trouble swallowing, or new shortness of breath. These symptoms can indicate many conditions, most of them not cancer, but they warrant a thyroid ultrasound and evaluation. Also flag significant changes in energy, weight, or heart rate that don't fit the expected Ozempic pattern — your prescriber may want to check TSH.

Ozempic and Thyroid: C-Cell Concerns, Contraindications, and What the Research Actually Shows

Open any Ozempic carton and you'll see the same warning in bold at the top of the package insert: a boxed caution about medullary thyroid carcinoma. For a lot of patients — especially those who've noticed a neck nodule on ultrasound or have a family member with thyroid disease — that warning lands with real weight.

The story behind that boxed warning is unusual. It came from rodent studies, not human trials. And the human data collected in the decade since Ozempic's approval has repeatedly failed to confirm the risk. But there are specific thyroid conditions that do make Ozempic genuinely off-limits, and those distinctions matter.

Where the Warning Comes From

During preclinical development of GLP-1 receptor agonists, rats given high doses developed C-cell hyperplasia and medullary thyroid tumors at statistically significant rates. C-cells are the parafollicular cells of the thyroid that produce calcitonin; they're distinct from the follicular cells that make thyroid hormone and that are involved in the far more common papillary and follicular thyroid cancers.

The FDA required a boxed warning for the entire GLP-1 class based on those rodent findings. The question of whether the rat C-cell biology translates to humans has been debated since Byetta (exenatide) first launched in 2005. Key anatomical differences between rodent and human thyroids — notably, humans have far fewer C-cells and different GLP-1 receptor expression in those cells — led many endocrinologists to doubt the translation.

What the Human Data Shows

A 2024 systematic review published in the International Journal of Molecular Sciences specifically examined thyroid carcinogenic risk in semaglutide patients, pulling from ten randomized controlled trials with 14,550 participants and 7,830 semaglutide users. The incidence of thyroid cancer in treated patients was less than 1%, with no statistically significant increased risk compared to controls. [PubMed: PMID 38673931]

A 2023 meta-analysis specifically on semaglutide and cancer outcomes found an odds ratio of 2.04 for thyroid cancer with a 95% confidence interval of 0.33 to 12.61 — a range that includes no effect and reflects how few events there are to analyze. The conclusion: no statistically significant association. [PubMed: PMID 37531876]

SUSTAIN-6, the 104-week cardiovascular outcomes trial of 3,297 patients with type 2 diabetes, also collected thyroid-related adverse event data. No excess of thyroid cancer was reported in the semaglutide group. [PubMed: PMID 27633186]

The picture that emerges: the signal that showed up unmistakably in rats has not replicated in humans across more than 15 years of GLP-1 prescribing.

When Ozempic Is Genuinely Contraindicated

Despite the reassuring human data on overall thyroid cancer risk, there are two absolute contraindications to semaglutide that involve the thyroid, and they aren't suggestions — they're on the label:

1. Personal or Family History of Medullary Thyroid Carcinoma (MTC)

MTC is a rare thyroid cancer that originates in the C-cells — the same cells implicated in the rodent studies. It accounts for only about 1–2% of thyroid cancers overall. If you or a first-degree relative has had MTC, semaglutide is contraindicated. The theoretical risk is that even if the human baseline signal is weak, someone with an existing C-cell susceptibility could be at genuine elevated risk.

2. Multiple Endocrine Neoplasia Type 2 (MEN2)

MEN2 is a hereditary cancer syndrome caused by mutations in the RET proto-oncogene. Nearly 100% of MEN2 patients develop medullary thyroid cancer, typically at young ages. If you have a confirmed MEN2A or MEN2B diagnosis — or if you have a first-degree relative with MEN2 and you haven't been genetically tested — semaglutide is contraindicated.

What About Common Thyroid Conditions?

The vast majority of thyroid conditions are not contraindications to Ozempic:

Hypothyroidism / Hashimoto's thyroiditis. These involve follicular cells, not C-cells. There's no biological rationale linking Ozempic to worsening of primary hypothyroidism, and clinical experience supports safety. Dosing of levothyroxine may need adjustment if significant weight loss occurs, since dose is weight-based for many patients.
Hyperthyroidism / Graves' disease. Also not a contraindication. Coordinate with your endocrinologist on timing and dosing, especially if thyroid function is actively unstable.
Thyroid nodules (benign). Common finding on ultrasound — up to 60% of adults have some nodules. Benign nodules are not a contraindication. New or changing nodules during Ozempic use should be evaluated, same as they would be in any patient.
Papillary or follicular thyroid cancer history. These cancers arise from follicular cells, not C-cells. Historical papillary or follicular thyroid cancer is not listed as a contraindication to semaglutide, though some oncologists prefer caution. Decisions here are individualized.
Thyroidectomy. If you've had your entire thyroid removed, there are no C-cells to worry about. Ozempic is not contraindicated. Again, levothyroxine dosing may need adjustment as weight changes.

Should You Screen Your Thyroid Before Starting?

The FDA label does not require thyroid screening before starting Ozempic. The label specifies that calcitonin monitoring (the blood marker for C-cell activity) has "uncertain value" for early detection of MTC in patients without pre-existing risk factors. Most endocrinologists do not order baseline calcitonin screening on otherwise asymptomatic patients.

That said, a few scenarios do warrant evaluation before starting:

Any palpable thyroid nodule or neck mass
Persistent hoarseness or voice changes without explanation
Unexplained elevated calcitonin on prior labs
Known family history of thyroid cancer of unclear type — consider asking whether it was medullary
Known RET mutation or strong family history of endocrine tumors

A simple thyroid ultrasound and, in higher-risk scenarios, a calcitonin level can clarify things before you start treatment.

Symptoms That Warrant Evaluation During Treatment

Once you're on Ozempic, the label directs patients to report:

A lump or swelling in the neck
Persistent hoarseness
Trouble swallowing
Shortness of breath that's new or progressive

These symptoms can indicate any number of conditions, most of them not cancer. But for someone on a GLP-1 drug, they're worth a proactive thyroid ultrasound and a conversation with your prescriber.

The Context: Thyroid Cancer Rates in the General Population

Context helps here. Papillary thyroid cancer — the most common type, which accounts for roughly 80% of thyroid cancers — is increasingly diagnosed, partly because ultrasound detects more small, clinically insignificant tumors. Incidence has been rising for decades, predating the GLP-1 era by thirty years. Against that background, identifying a small signal from a specific drug class is statistically challenging and requires very large datasets.

Medullary thyroid cancer, the specific cancer of concern with GLP-1 drugs, is rare — a lifetime incidence of about 1 in 100,000 in the general population, overwhelmingly concentrated among people with RET mutations or family history. That rarity is part of why human studies haven't definitively answered the question one way or the other: the events are simply uncommon enough that even large trials don't produce many cases.

What the Calcitonin Test Actually Tells You

Calcitonin is a peptide hormone produced by thyroid C-cells. Because medullary thyroid carcinoma arises from C-cells, elevated calcitonin can indicate MTC. But calcitonin also rises for lots of benign reasons — smoking, chronic kidney disease, proton pump inhibitor use, and several other conditions — which limits its usefulness as a general screening tool.

The FDA semaglutide label explicitly states that the value of routine calcitonin monitoring in asymptomatic patients without risk factors is uncertain. Most endocrinologists reserve calcitonin testing for patients with suspicious ultrasound findings, family history, known RET mutations, or unexplained neck symptoms.

If calcitonin is ordered and comes back elevated, it doesn't automatically mean cancer. Mild elevations are common and often non-specific. Significantly elevated calcitonin (typically greater than 100 pg/mL) warrants further workup with imaging and potentially a provocative stimulation test.

Semaglutide After Thyroidectomy

One question that comes up frequently: is Ozempic safe if you've had your thyroid removed? The answer is generally yes. Without thyroid tissue, there are no C-cells to be affected. The original rodent concern simply doesn't apply. Your levothyroxine dose may need adjustment as weight changes, but that's true of any weight-changing intervention and isn't a reason to avoid the drug.

The only complication: if your thyroidectomy was for medullary thyroid cancer specifically, then the boxed contraindication still applies — not because residual cancer could be affected by semaglutide, but because active or recent MTC remains a labeled contraindication. Discuss with your oncologist.

Evolving Regulatory Position

The FDA, the European Medicines Agency, and Health Canada have all retained the medullary thyroid cancer warning on semaglutide labels despite the accumulating human evidence, reflecting a cautious regulatory stance while long-term data continues to mature. Ongoing post-market surveillance and registry studies will continue to refine the picture. For now, the working consensus among endocrinologists is that Ozempic poses no measurable thyroid cancer risk to the general patient population while remaining contraindicated in the small subset with MTC or MEN2 history.

Practical Takeaways

The boxed warning is based on rats, not people. More than a decade of human data has consistently failed to confirm the rodent signal. The risk to most patients appears very low.
Personal or family history of MTC or MEN2 is an absolute contraindication. This is the one place where the warning has real force — don't start Ozempic if either applies to you.
Most thyroid conditions are not contraindications. Hashimoto's, Graves', hypothyroidism, hyperthyroidism, and benign nodules don't rule out Ozempic.
Rapid weight loss can affect levothyroxine dosing. If you're on thyroid hormone replacement, expect your TSH to be rechecked once you've had significant weight loss — dose adjustments are common.
Don't routinely screen with calcitonin. The FDA explicitly notes uncertain value in asymptomatic patients without risk factors. Targeted screening is appropriate if you have neck nodules, voice changes, or family history of thyroid cancer of unclear type.
Report new neck symptoms. A new lump, persistent hoarseness, or trouble swallowing warrants an ultrasound — regardless of which medications you're on.

The thyroid conversation around Ozempic has produced a lot more fear than the evidence supports for most patients. It's also produced some under-appreciated real contraindications for a smaller subset. Knowing which group you're in is the whole point of the pre-prescription conversation.